1. Scrip
  2. >>Business

AstraZeneca’s Business Development Head Grady Outlines Strategy Mix

 
• By Sten Stovall

AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.

Head of business development at AstraZeneca, Shaun Grady
Shaun Grady, AstraZeneca Business Development Chief • Source: AstraZeneca PLC

AstraZeneca PLC's externalization strategy in the future will probably engage more in partnering collaborations with other drug makers that generate recurring revenue and focus less on the sell-off of mature therapies that don’t fit the pharma’s pipeline strategy, Head of Business Development Shaun Grady told Scrip.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business